tirzepatide and bone loss Tirzepatide, a dual GLP-1 GIP receptor agonist, promotes in obese mice via gut microbial-related metabolites GLP-1s and Bone Health: What

Starting at lower doses minimizes the risk of severe gastrointestinal side effects and allows individuals to adapt to the peptide's effects on gastric emptying and appetite

How to Protect Your Kidneys While Taking GLP-1 Drugs The good news is that the one real risk dehydration is also the most controllable

Some studies have shown that results can be achieved on microdoses, but they havent been validated in evidence-based guidelines, says DeGore

While the new indication for the drug means the TGA has satisfactory evidence of its benefits in regard to those particular conditions, it did not alter the cost of the drug

Understanding how tirzepatide dosing worksand what "maximum dose" actually means for your bodyhelps set realistic expectations and prevents unnecessary dose escalation

In clinical trial follow-ups, most participants began regaining weight within the first 3 months after stopping GLP-1 therapy